-
Trends in men’s facial hair impact sales
The shave category is trying to get its groove back. With the exception of razors, where sales are up a healthy 10.6% for the 52-week period ended Sept. 4, 2016, as tracked by IRI across multi-outlets, all of the other categories in shave are down.
(To view the full Shave Report, click here.)
-
Private label, Bayer drive down internal analgesics
Internal analgesics is slightly down in retail sales with a 0.6% decrease year-over-year. As the largest segment in internal analgesics, tablets were down 0.4%. This performance was driven down primarily by private label and Bayer products. Private-label internal analgesics were down 5%, and Bayer was down 4%. Pfizer saw no change in sales. McNeil’s return to the market did well, reflecting a 17% increase over the same time period last year. The external analgesic category was up 7% year-over-year.